{"id":"low-dose-nadroparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL2109204","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nadroparin is derived from unfractionated heparin through chemical depolymerization, resulting in a low-molecular-weight heparin (LMWH) with a molecular weight of 4,300 Da. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa (anti-Xa activity) and to a lesser extent thrombin (factor IIa). The low-dose formulation is used for thromboprophylaxis in clinical settings where prevention of venous thromboembolism is indicated.","oneSentence":"Low-dose nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:21.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in surgical patients"},{"name":"Thromboprophylaxis in medical patients at risk of venous thromboembolism"},{"name":"Treatment of deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum","enrollment":9200},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT02987946","phase":"NA","title":"Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2016-12","conditions":"Deep-Venous Thrombosis","enrollment":280},{"nctId":"NCT06494878","phase":"PHASE3","title":"The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-04","conditions":"Venous Thromboembolism, Postpartum Period, Aspirin","enrollment":8805},{"nctId":"NCT04507178","phase":"PHASE2","title":"Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-02-02","conditions":"Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia","enrollment":100},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT04067505","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-18","conditions":"May-Thurner Syndrome","enrollment":224},{"nctId":"NCT06319131","phase":"NA","title":"Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-01","conditions":"Portal Vein Thrombosis","enrollment":84},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":"COVID, Thrombosis, Pulmonary Embolism","enrollment":1000},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT04173429","phase":"PHASE4","title":"Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Liver Cirrhosis, Portal Vein Thrombosis","enrollment":64},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":"Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss","enrollment":420},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02247414","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection","status":"COMPLETED","sponsor":"Yangzhou University","startDate":"2014-09","conditions":"Cirrhosis, Hypertension, Status;Splenectomy","enrollment":124},{"nctId":"NCT02238444","phase":"PHASE4","title":"Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy","status":"UNKNOWN","sponsor":"Yangzhou University","startDate":"2014-09-01","conditions":"Cirrhosis, Hypertension, Venous Thrombosis","enrollment":60},{"nctId":"NCT00421538","phase":"PHASE3","title":"Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2008-01","conditions":"Distal (Calf) Deep-vein Thrombosis","enrollment":260},{"nctId":"NCT00312013","phase":"PHASE3","title":"Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Thrombosis, Venous","enrollment":503},{"nctId":"NCT02526303","phase":"NA","title":"Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis","status":"WITHDRAWN","sponsor":"Air Force Military Medical University, China","startDate":"","conditions":"Liver Cirrhosis, Portal Vein Thrombosis, Anticoagulation","enrollment":""},{"nctId":"NCT02957877","phase":"PHASE4","title":"LMWH Infusion as Anticoagulation for Home HD","status":"UNKNOWN","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2016-03","conditions":"Endstage Renal Disease","enrollment":12},{"nctId":"NCT01542762","phase":"NA","title":"Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-03","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1500},{"nctId":"NCT01542723","phase":"NA","title":"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-05","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1500},{"nctId":"NCT00700895","phase":"PHASE3","title":"Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2006-08","conditions":"Indications for Warfarin Therapy","enrollment":320},{"nctId":"NCT02630095","phase":"PHASE4","title":"The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-12","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":96},{"nctId":"NCT02398357","phase":"PHASE4","title":"The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-03","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":96},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT02295150","phase":"PHASE4","title":"Prophylaxis of Venous Thromboembolism After Bariatric Surgery","status":"UNKNOWN","sponsor":"Rijnstate Hospital","startDate":"2013-03","conditions":"Morbid Obesity, Thromboembolism, Bypass Complications","enrollment":50},{"nctId":"NCT01531829","phase":"PHASE4","title":"Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2009-07","conditions":"Pulmonary Thromboembolisms, Pulmonary Embolism","enrollment":460},{"nctId":"NCT00796692","phase":"PHASE4","title":"Nadroparin for the Initial Treatment of Pulmonary Thromboembolism","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism, Vascular Diseases","enrollment":274},{"nctId":"NCT00669721","phase":"NA","title":"OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2008-03","conditions":"Renal Failure, Hemodialysis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nadroparin","Fraxiparin"],"phase":"marketed","status":"active","brandName":"Low dose nadroparin","genericName":"Low dose nadroparin","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose nadroparin is used to prevent Venous Thromboembolism (VTE) after bariatric surgery. It works by activating Antithrombin-III, a protein that helps regulate blood clotting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}